Testing new MRI scans to improve prostate cancer diagnosis and grading
Compares new MRI scan methods with standard scans in men suspected of having prostate cancer.
Plain-language title generated from the registry record
Registry title: The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center
Key facts
- Where
- Suzhou, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with a strong suspicion of prostate cancer and a raised tPSA level. They will have both usual and new MRI scans to test how well the new scans diagnose and grade the cancer.
- Age
- 20 Years to 90 Years
- Sex
- Men only
- Disease stage
- Strong clinical suspicion of prostate cancer with a raised tPSA level.
- Earlier treatment
- Must not have had treatment for prostate cancer before the MRI, such as endocrine therapy or radiotherapy. Must not have had radical prostatectomy for prostate cancer. No treated malignant tumour in the past.
- Biomarker or test result
- Raised tPSA level.
Main reasons for not taking part
- History of another tumour or a malignant tumour that was treated
- Prostate cancer treatment before the MRI, such as endocrine therapy or radiotherapy
- Earlier radical prostatectomy for prostate cancer
- Claustrophobia
- Pacemaker, cardiac stent, or metal implants such as screws and plates
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 90 years old?
Source: NCT07552285, who can take part
Where in China
- The First Affiliated Hospital of Soochow UniversitySuzhou, ChinaContact: Gang ChenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The First Affiliated Hospital of Soochow University
- Trial code
- NCT07552285
- Record updated
- 27 April 2026
- Original description
The goal of this clinical trial aims to explore the diagnostic efficacy and grading of prostate cancer by a novel MRI sequences such as MAGiC，OGSE,CEST,IVIM,etc.The main question it aims to answer is:Read full original descriptionShow less
The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center
The goal of this clinical trial aims to explore the diagnostic efficacy and grading of prostate cancer by a novel MRI sequences such as MAGiC，OGSE,CEST,IVIM,etc.The main question it aims to answer is:
Can the novel non-contrast multiparametric MRI imaging improve the accuracy of diagnosis and grading of prostate cancer? For patients with clinical suspicion of prostate cancer, both conventional and new sequences magnetic resonance scans are conducted, with surgical or biopsy pathological results serving as the gold standard.
Inclusion: Patients with a high clinical suspicion of prostate cancer and elevated tPSA levels; Patients with no prior history of other tumors; Patients with no contraindications to MRI, including claustrophobia, presence of pacemakers, cardiac stents, or metal implants such as screws and plates.
Exclusion: Prior to the MRI examination, the patient has undergone treatment for prostate cancer, including endocrine therapy, radiotherapy, etc; Patients who have previously undergone radical prostatectomy for prostate cancer; The patient has a history of malignant tumors and has received corresponding treatment.